Shots:
- AbbVie led the global immunology market with $30.4B in immunology revenue in 2025, followed by Sanofi ($19.08B) and Johnson & Johnson ($15.72B). Continued demand for biologics and targeted therapies across autoimmune and inflammatory diseases supported strong commercial performance among leading companies.
- The global immunology market, valued at $108.4B in 2024, is projected to reach $286.4B by 2034, expanding at a CAGR of 10.2% from 2025 to 2034. Growth is driven by an ageing population, the rising prevalence of immune-mediated disorders, increasing biologics adoption, and continued innovation in IL-17, IL-23, JAK, TYK2, and anti-IgE therapies.
- The report is based on immunology segment revenues reported during fiscal year 2025, encompassing both established and next-generation therapies to deliver a comprehensive ranking of the world’s leading immunology companies. It highlights the strong commercial momentum of leading brands, including Skyrizi, Rinvoq, Dupixent, Tremfya, Bimzelx, Vyvgart, Cosentyx, Sotyktu, Saphnelo, and Ebglyss, while showcasing the innovative therapies reshaping the immunology landscape across autoimmune, inflammatory, and rare immune-mediated diseases.
20. Incyte
Immunology Segment Revenue: $0.82B
Founded Year: 2002
Market Cap: $23.3B
Total Employees: 2,800
Headquarters: Delaware, United States
Stock Exchange: NASDAQ
- Incyte researches, develops, and commercializes innovative medicines focused on oncology, immunology, and inflammation, with an emphasis on targeted therapies for immune-mediated diseases
- Olumiant and Opzelura are Incyte’s leading immunology products. In 2025, the company’s immunology revenue increased to $0.82B from $0.64B in 2024, recording a 28.1% increase over the previous year, primarily driven by strong demand and higher refill rates for Opzelura in the US across atopic dermatitis and vitiligo
- In June 2026, Incyte reported positive 24-week P-III (TRuE-AD4) study results for Opzelura (ruxolitinib) cream in patients with moderate atopic dermatitis, further supporting the expansion of its immunology portfolio
19. Organon & Co. (Sun Pharma)
Immunology Segment Revenue: $0.95B
Founded Year: 2020
Market Cap: N/A
Total Employees: 4,000
Headquarters: New Jersey, United States
Stock Exchange: NYSE
- Organon develops, manufactures, and commercializes medicines and biosimilars across women’s health, biosimilars, and established brands, including therapies for immunology and inflammatory diseases. In April 2026, Sun Pharma entered into a definitive agreement to acquire Organon in an all-cash transaction valued at approximately $11.75B
- Arcoxia, Hadlima, Brenzys, Vtama and Renflexis are Organon’s leading immunology products. In 2025, the company’s immunology revenue increased to $0.95B from $0.77B in 2024, reflecting a 23.37% increase over the previous year, primarily driven by higher sales across its immunology portfolio
- In June 2026, Organon and Samsung Bioepis expanded their commercialization agreement for Pyzchiva (ustekinumab), a biosimilar referencing Stelara (ustekinumab), to include the Canadian market
18. Astellas
Immunology Segment Revenue: $1.28B
Founded Year: 1923
Market Cap: $23.97B
Total Employees: 14,099
Headquarters: Tokyo, Japan
Stock Exchange: TYO
- Astellas researches, develops, manufactures, and commercializes innovative medicines across oncology, urology, ophthalmology, immunology, and other specialty therapeutic areas
- Prograf is Astellas’ leading immunology product, used to prevent organ transplant rejection by suppressing the immune system. In 2025, the company’s immunology revenue declined to approximately $1.28B from $1.31B in 2024, reflecting a 2.3% decrease from the previous year, primarily due to lower sales of Prograf
- In May 2026, Astellas unveiled its five-year strategic plan, shifting its R&D focus toward targeted immuno-oncology and advancing ASP2138, a bispecific T-cell engager targeting CLDN18.2 for the treatment of gastric and pancreatic cancers
17. Merck KGaA
Immunology Segment Revenue: $1.95B
Founded Year: 1668
Market Cap: $67.74B
Total Employees: 62,500
Headquarters: Darmstadt, Germany
Stock Exchange: ETR
- Merck KGaA researches, develops, manufactures, and commercializes innovative medicines across healthcare, life science, and electronics, with a focus on immunology, oncology, neurology, fertility, and endocrinology
- Mavenclad and Rebif are Merck KGaA’s leading immunology products. In 2025, the company’s immunology revenue increased to $1.95B from $1.75B in 2024, reflecting an 11.4% increase over the previous year, primarily driven by higher sales of Mavenclad
- In July 2026, the US FDA granted Breakthrough Therapy Designation to enpatoran for the treatment of lupus patients with active cutaneous manifestations
16. GSK
Immunology Segment Revenue: $2.39B
Founded Year: 2000
Market Cap: $104.02B
Total Employees: 66,800
Headquarters: London, United Kingdom
Stock Exchange: LON
- GSK researches, develops, manufactures, and commercializes innovative medicines and vaccines across immunology, infectious diseases, respiratory diseases, oncology, HIV, and other therapeutic areas
- Benlysta is GSK’s leading immunology product. In 2025, the company’s immunology revenue increased to $2.39B from $1.87B in 2024, reflecting an 27.8% increase from the previous year, driven by strong demand, higher treatment volumes, and increased biologic penetration across multiple markets
- In February 2026, GSK agreed to acquire 35Pharma for up to $950M, strengthening its immunology and respiratory pipeline with the addition of GSK’227, an investigational biologic targeting inflammatory diseases
15. Pfizer
Immunology Segment Revenue: $2.64B
Founded Year: 1849
Market Cap: $143.28B
Total Employees: 75,000
Headquarters: New York, United States
Stock Exchange: NYSE
- Pfizer researches, develops, manufactures, and commercializes innovative medicines and vaccines across immunology, oncology, internal medicine, inflammation, rare diseases, and infectious diseases
- Xeljanz, Enbrel, Inflectra/Remsima, Cibinqo, and Litfulo are Pfizer’s leading immunology products. In 2025, the company’s immunology revenue was $2.64B, compared with $2.65B in 2024, remaining essentially flat with a marginal 0.4% decline, primarily due to lower sales of Xeljanz and Enbrel
- In January 2026, Pfizer entered into a $530M agreement with Novavax to utilize its adjuvant technology in product development, supporting the advancement of next-generation vaccine and immunology programs
14. Eli Lilly
Immunology Segment Revenue: $2.96B
Founded Year: 1876
Market Cap: $1.10T
Total Employees: 50,000
Headquarters: Indianapolis, United States
Stock Exchange: NYSE
- Eli Lilly researches, develops, manufactures, and commercializes innovative medicines across immunology, diabetes, obesity, oncology, neuroscience, and other therapeutic areas
- Taltz, Olumiant, and other immunology products comprise Eli Lilly’s immunology portfolio. In 2025, the company’s immunology revenue increased to $2.96B from $2.45B in 2024, recording a 20.8% increase over the previous year, primarily driven by higher sales across its immunology portfolio
- In July 2026, the USFDA approved Ebglyss (lebrikizumab-lbkz) as an every-8-week (Q8W) maintenance treatment for adults and adolescents with moderate-to-severe atopic dermatitis
13. Argenx N.V.
Immunology Segment Revenue: $4.15B
Founded Year: 2008
Market Cap: $52.73B
Total Employees: 1,900
Headquarters: Amsterdam, Netherlands
Stock Exchange: EBR
- Argenx N.V. researches, develops, and commercializes innovative antibody-based therapies focused on treating severe autoimmune diseases and rare immune-mediated disorders
- Vyvgart is Argenx’s flagship immunology product. In 2025, the company’s immunology revenue increased to $4.15B from $2.18B in 2024, representing a remarkable 90.4% increase from 2024, driven by strong global commercialization of Vyvgart and continued regulatory approvals across multiple markets
- In June 2026, the USFDA approved Vyvgart and Vyvgart Hytrulo for adults with generalized myasthenia gravis (gMG), further expanding Argenx’s immunology portfolio and patient access
12. Bristol-Myers Squibb
Immunology Segment Revenue: $4.57B
Founded Year: 1887
Market Cap: $123.57B
Total Employees: 32,500
Headquarters: New Jersey, United States
Stock Exchange: NYSE
- Bristol-Myers Squibb researches, develops, manufactures, and commercializes innovative medicines across oncology, hematology, immunology, cardiovascular, neuroscience, and other therapeutic areas
- Orencia, Sotyktu, and Zeposia are Bristol-Myers Squibb’s leading immunology products. In 2025, the company’s immunology revenue increased to $4.57B from US$4.49B in 2024, reflecting a 1.8% increase over the previous year, driven by overall growth in sales across its immunology portfolio
- In June 2026, Bristol-Myers Squibb entered a potential $15.2B collaboration with Hengrui Pharma to advance 13 early-stage programs across oncology, hematology, and immunology, further strengthening its immunology pipeline
11. Biogen
Immunology Segment Revenue: $4.73B
Founded Year: 1978
Market Cap: $30.84B
Total Employees: 7,500
Headquarters: Massachusetts, United States
Stock Exchange: NASDAQ
- Biogen researches, develops, manufactures, and commercializes innovative medicines across neurology, immunology, rare diseases, and specialized therapeutics
- Tysabri, Flixabi (biosimilar), Tecfidera, Vumerity, and Avonex are Biogen’s leading immunology products. In 2025, the company’s immunology revenue declined to $4.73B from $5.03B in 2024, reflecting a 6.0% decrease from the previous year, primarily due to lower Tysabri sales amid increasing competition, including the impact of biosimilar entrants in Europe
- In June 2026, Biogen agreed to acquire RayThera to expand its immunology pipeline, adding novel therapeutic candidates aimed at treating immune-mediated diseases and strengthening its long-term inflammation portfolio
10. UCB
Immunology Segment Revenue: $5.56B
Founded Year: 1928
Market Cap: $52.85B
Total Employees: 9,800
Headquarters: Brussels, Belgium
Stock Exchange: EBR
- UCB researches, develops, manufactures, and commercializes innovative medicines across immunology, neurology, and rare diseases, with a strong focus on severe immune-mediated disorders
- Cimzia, Bimzelx, Rystiggo and Zilbrysq are UCB’s leading immunology products. In 2025, the company’s immunology revenue increased to $5.56B from $3.03B in 2024, surging 83.49% compared to the previous year, primarily driven by the successful global launches of Bimzelx
- In May 2026, UCB agreed to acquire Candid Therapeutics for up to $2.2B, expanding its immunology pipeline with next-generation T-cell engager therapies for autoimmune diseases
09. Regeneron Pharmaceuticals
Immunology Segment Revenue: $5.88B
Founded Year: 1988
Market Cap: $71.18B
Total Employees: 15,300
Headquarters: New York, United States
Stock Exchange: NASDAQ
- Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes innovative medicines across immunology, oncology, ophthalmology, cardiovascular, infectious diseases, and rare diseases
- Dupixent and Kevzara are Regeneron’s leading immunology products. In 2025, the company’s immunology revenue increased to $5.88B from $4.53B in 2024, representing a 29.8% year-over-year increase, primarily driven by higher sales of its immunology portfolio
- In June 2026, Regeneron highlighted the expansion of its immunology portfolio and pipeline, showcasing positive clinical progress across multiple investigational therapies for allergic, inflammatory, and autoimmune diseases
08. Takeda
Immunology Segment Revenue: $6.81B
Founded Year: 1781
Market Cap: $54.11B
Total Employees: 47,029
Headquarters: Tokyo, Japan
Stock Exchange: TYO
- Takeda researches, develops, manufactures, and commercializes innovative medicines across gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines
- Entyvio is Takeda’s key immunology product. In 2025, the company’s immunology revenue increased to $6.81B from $6.43B in 2024, reflecting a 5.9% increase over the previous year, driven by overall growth in sales across its plasma-derived therapies portfolio
- In July 2026, Takeda reported positive Phase III LATITUDE-ATLAS study results for zasocitinib, demonstrating significant efficacy in adults with moderate-to-severe plaque psoriasis
07. Roche
Immunology Segment Revenue: $7.01B
Founded Year: 1896
Market Cap: $337.02B
Total Employees: 1,12,800
Headquarters: Basel, Switzerland
Stock Exchange: SWX
- Roche researches, develops, manufactures, and commercializes innovative pharmaceuticals and diagnostics across oncology, immunology, neuroscience, ophthalmology, and other therapeutic areas
- Actemra/RoActemra, Xolair, and MabThera/Rituxan are Roche’s leading immunology products. In 2025, the company’s immunology revenue increased to $7.01B from $5.66B in 2024, representing a 23.9% year-over-year increase, driven by strong growth of Xolair in food allergy and the USFDA approvals of Gazyva/Gazyvaro for lupus nephritis and systemic lupus erythematosus
- In July 2026, Roche entered into a collaboration and licensing agreement worth up to US$3B with Nurix Therapeutics to develop bexobrutideg, an oral BTK degrader, further strengthening its immunology pipeline for autoimmune diseases
06. AstraZeneca
Immunology Segment Revenue: $7.24B
Founded Year: 1999
Market Cap: $260.33B
Total Employees: 96,100
Headquarters: Cambridge, United Kingdom
Stock Exchange: LON
- AstraZeneca researches, develops, manufactures, and commercializes innovative medicines across oncology, biopharmaceuticals, and rare diseases, with a growing focus on immunology and inflammation
- Saphnelo, Soliris, and Ultomiris are AstraZeneca’s leading immunology products. In 2025, the company’s immunology revenue increased to $7.24B from $6.98B in 2024, representing a 3.7% year-over-year increase, primarily driven by higher sales of Ultomiris
- In June 2026, AstraZeneca announced positive Phase III MIRANDA study results for tozorakimab, an anti-IL-33 monoclonal antibody, marking the third successful Phase III study in COPD and further strengthening its immunology and respiratory pipeline
05. Amgen
Immunology Segment Revenue: $7.3B
Founded Year: 1980
Market Cap: $200.54B
Total Employees: 31,500
Headquarters: California, United States
Stock Exchange: NASDAQ
- Amgen discovers, develops, manufactures, and commercializes innovative biologic medicines across inflammation, oncology, cardiovascular, bone health, nephrology, and rare diseases
- Enbrel, Otezla, Tezspire, and Krystexxa are Amgen’s key immunology products. In 2025, the company’s immunology revenue declined to $7.30B from $7.59B in 2024, down 3.8% from 2024, primarily due to lower sales of Enbrel
- In June 2026, Amgen reported positive Phase III study results for Tepezza (teprotumumab-trbw) in patients with active thyroid eye disease, further strengthening its immunology portfolio
04. Novartis
Immunology Segment Revenue: $10.29B
Founded Year: 1996
Market Cap: $312.33B
Total Employees: 75,300
Headquarters: Basel, Switzerland
Stock Exchange: SWX
- Novartis researches, develops, manufactures, and commercializes innovative medicines across immunology, cardiovascular, renal, metabolic, neuroscience, oncology, and other therapeutic areas
- Cosentyx, Xolair, Rhapsido and Ilaris are Novartis’ key immunology products. In 2025, the company’s immunology revenue increased to $10.29B from $9.29B in 2024, marking a 10.8% growth compared to 2024, primarily driven by strong sales growth of Cosentyx and Ilaris
- In March 2026, Novartis agreed to acquire Excellergy for up to $2B, adding the Phase I anti-IgE candidate Exl-111 to strengthen its allergy and immunology pipeline for IgE-driven diseases
03. Johnson & Johnson
Immunology Segment Revenue: $15.72B
Founded Year: 1886
Market Cap: $601.73B
Total Employees: 138,200
Headquarters: New Jersey, United States
Stock Exchange: NYSE
- Johnson & Johnson researches, develops, manufactures, and commercializes innovative medicines across immunology, oncology, neuroscience, cardiovascular, pulmonary hypertension, and other therapeutic areas
- Remicade, Simponi/Simponi Aria, Stelara, and Tremfya are Johnson & Johnson’s key immunology products. In 2025, the company’s immunology revenue declined to $15.72B from $17.82B in 2024, reflecting an 11.8% decline from the previous year, primarily due to lower Stelara (ustekinumab) sales following biosimilar competition and the impact of the Medicare Part D redesign
- In June 2026, the USFDA approved a label expansion for Tremfya (guselkumab) to help inhibit the progression of structural joint damage in adults with active psoriatic arthritis
02. Sanofi
Immunology Segment Revenue: $19.08B
Founded Year: 1973
Market Cap: $107.01B
Total Employees: 74,800
Headquarters: Paris, France
Stock Exchange: NASDAQ
- Sanofi researches, develops, manufactures, and commercializes innovative medicines and vaccines across immunology, rare diseases, oncology, neurology, and other therapeutic areas
- Dupixent and Kevzara are Sanofi’s leading immunology products. In 2025, the company’s immunology revenue increased to $19.08B from $12.32B in 2024, representing a 54.9% year-over-year increase, primarily driven by higher sales of Dupixent and Kevzara
- In June 2026, Wayrilz (rilzabrutinib) received approval in Japan for the treatment of persistent or chronic immune thrombocytopenia (ITP), expanding Sanofi’s immunology portfolio
01. AbbVie
Immunology Segment Revenue: $30.4B
Founded Year: 2013
Market Cap: $449.45B
Total Employees: 57,000
Headquarters: Illinois, United States
Stock Exchange: NYSE
- AbbVie discovers, develops, manufactures, and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, and other chronic and complex diseases
- Humira, Skyrizi, and Rinvoq are AbbVie’s leading immunology products. In 2025, the company’s immunology revenue increased to $30.4B from $26.68B in 2024, representing a 13.9% increase from 2024, primarily driven by the continued strong growth of Skyrizi and Rinvoq
- In June 2026, the US FDA approved Skyrizi (risankizumab) for pediatric patients aged six years and older with moderate-to-severe plaque psoriasis and active psoriatic arthritis, expanding AbbVie’s immunology portfolio into pediatric psoriatic disease
Criteria:
- The report is based on immunology segment revenues reported during fiscal year 2025, encompassing both established and next-generation therapies to deliver a comprehensive ranking of the world’s leading immunology companies
- For companies with non-December fiscal year endings, revenue has been calculated for the January–December 2025 period using quarterly and annual financial filings. Where vaccine-specific sales were not disclosed, estimates were derived from publicly available company reports and credible secondary sources
- Market capitalisation is considered as of 17 July 2026. Revenues reported in different currencies have been converted into US dollars using exchange rates as of 31 December 2025 to ensure consistency across all rankings
Source:
- Company Websites
- Press Releases
- Annual Reports
- Quarterly Reports
- Google Finance
- OANDA
Related Post: Top 20 Immunology Companies of 2025